Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Traws Pharma (TRAW) EBITDA (2016 - 2025)

Historic EBITDA for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to -$4.1 million.

  • Traws Pharma's EBITDA rose 5249.53% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.8 million, marking a year-over-year increase of 8884.91%. This contributed to the annual value of -$142.4 million for FY2024, which is 60141.89% down from last year.
  • As of Q3 2025, Traws Pharma's EBITDA stood at -$4.1 million, which was up 5249.53% from -$1.2 million recorded in Q2 2025.
  • In the past 5 years, Traws Pharma's EBITDA registered a high of -$1.2 million during Q2 2025, and its lowest value of -$123.3 million during Q2 2024.
  • Over the past 5 years, Traws Pharma's median EBITDA value was -$4.6 million (recorded in 2021), while the average stood at -$11.0 million.
  • In the last 5 years, Traws Pharma's EBITDA plummeted by 257566.16% in 2024 and then skyrocketed by 9898.74% in 2025.
  • Traws Pharma's EBITDA (Quarter) stood at -$3.8 million in 2021, then tumbled by 52.38% to -$5.7 million in 2022, then increased by 22.18% to -$4.5 million in 2023, then dropped by 18.29% to -$5.3 million in 2024, then grew by 23.17% to -$4.1 million in 2025.
  • Its last three reported values are -$4.1 million in Q3 2025, -$1.2 million for Q2 2025, and -$5.2 million during Q1 2025.